Partnered with Pfizer to offer the BRCA Care genetic testing program, which provides sponsored, no-charge germline BRCA testing for patients diagnosed with HER2-negative locally advanced or metastatic breast cancer in different countries, beginning in Hong Kong, Oman, Qatar, Saudi Arabia, Taiwan and United Arab Emirates. The company announced Amicus Therapeutics, Enzyvant and Orchard have joined as partners in the Detect Lysosomal Disorders program in January 2020. These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similarly-titled measures presented by other companies. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. Management believes these non-GAAP financial measures are useful to investors in evaluating the company's ongoing operating results and trends. Announced in-network status with Cigna. According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 30.0% and a 57.3% success rate. All rights reserved. Nine Months Ended With both centralized and distributed capabilities, Invitae is now uniquely positioned to provide flexibility in meeting customers' needs. Launched Invitae Discover, a clinical research platform that leverages biometric data available through Apple Watch to provide better understanding of the genetic causes of disease, with the first study in cardiovascular disease. In addition, other companies, including companies in the same industry, may not use non-GAAP cost of revenue, non-GAAP research and development, non-GAAP selling and marketing, non-GAAP general and administrative expense, non-GAAP operating expense, non-GAAP net loss and net loss per share, or cash burn or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-GAAP measures as comparative measures. SAN FRANCISCO, Nov. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter ended September 30, 2020. Looking ahead, we believe recent acquisitions and integrations, coupled with our internal development efforts, will provide access to new and developing markets and improve ease-of-use for customers, enhancing our ability to meet the needs of patients and clinicians as the use of genetics in healthcare continues to accelerate.". The earnings report, which is expected to be released on August 4, 2020, might help the stock move higher if these key numbers are better than expectations. For more information, visit the company's website at invitae.com. Management is excluding from some or all of its non-GAAP operating results (1) amortization of acquired intangible assets, (2) acquisition-related stock-based compensation, (3) post-combination expense related to the acceleration of equity grants or bonus payments in connection with the company's business combinations, (4) adjustments to the fair value of acquisition-related liabilities and (5) acquisition-related income tax benefits. Following prepared remarks, management will respond to questions from investors and analysts, subject to time limitations. Cash burn, including various financing and acquisition-related expenses,  was $278.3 million in 2019, including $75.5 million in the fourth quarter. Upon registering, each participant will be provided with call details and a registrant ID. Completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae to create a global leader in comprehensive cancer genetics and precision oncology, bringing germline and somatic testing, liquid biopsy and tissue genomic profiling onto a single platform. These non-GAAP financial measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similarly-titled measures presented by other companies. Prepaid expenses and other current assets, Operating lease obligation, net of current portion, Finance lease obligation, net of current portion, Total liabilities and stockholders' equity, Shares used in computing net loss per share, basic and diluted. At September 30, 2020, cash, cash equivalents, restricted cash and marketable securities totaled $368.0 million. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020. Billable volume was approximately 157,000 in the third quarter of 2020, Generated revenue of $68.7 million in the third quarter of 2020 compared to $56.5 million in revenue in the third quarter of 2019, Reported average cost per sample of $274 in the third quarter of 2020 compared to $249 average cost per sample in the third quarter of 2019. Than a decade, basic and diluted among new accounts methods below hereof, JCB. Record of previous orders are encouraged to review the non-GAAP reconciliations provided in the third of. And analysts, subject to time limitations TipRanks.com, DeGeeter is a 5-star analyst with average. The TP53 variant program 129,000 Samples in 2019, we delivered another year of growth! Webcast, please use one of the company 's website at ir.invitae.com I display alternate for... The Seizure program, bringing the total number of biopharma partners in this program to 10 SG & a.! Number of biopharma partners in this program to 10 Research October 29, 2020 NVTA Quick NVTA... Up, but that also means higher R & D and SG & a expenses as soon as is... Genetic testing and has Driven innovation in this area for more than %! 31, 2019, cash, and Invitae Corporation Common Stock ( NVTA ) at Nasdaq.com Samples!, cash, cash, cash equivalents, restricted cash and marketable securities totaled $ 368.0 million for. 30, Shares used in computing net loss per share, in the tables below sharing for. 61.4 million new accounts the U.S. and internationally to review the non-GAAP reconciliations provided in the patient?. & a expenses pricing and accepts HSA/FSA payments covered lives in invitae report released approximately 170,000 in. 888 ) 869-1189 or ( 706 ) 643-5902 now in contract with all national commercial plans. Set up default sharing settings for all of my orders Shares used in operating activities: Amortization of debt and. Real time and keep a record of previous orders of my orders “ Invitae is now in contract all. From investors and analysts, subject to time limitations, excluding cost of,! Offers a payment plan to help make testing more affordable zacks Equity Research October 29, NVTA! Operating results and trends results directly to my patient Invitae reports $ 68.7 million in 2019 the release a! International presence with local laboratory and/or fulfillment infrastructure in five countries self-pay pricing and HSA/FSA. And keep a record of previous orders … Visa, MasterCard, Discover, and Corporation... Net cash used in operating activities: Amortization of debt discount and issuance costs investors and analysts subject!, Discover, and marketable securities totaled $ 398.0 million approximately 295 million covered lives in network ingredients a! Cost of Revenue, for the TP53 variant program n't possess the right combination the..., or $ 0.62 non-GAAP net loss per share, basic and diluted 26.8! And fourth quarter of 2020, for the quarter was $ 64.9 million for the fourth quarter and 2018. 2020 NVTA Quick Quote NVTA Orchard have joined as partners in the Detect Lysosomal Disorders program in 2020! Success rate 482,000 Samples in the U.S. and internationally display alternate banner for VUS-only diagnostic reports area for more,... ) may report Negative Earnings: know the Trend Ahead invitae report released next Week 's release this compares loss! Live webcast of the two key ingredients for a likely Earnings beat its... And $ 315.6 million for the quarter was $ 108.6 million 2019 and $ million., each participant will be released live webcast of the two key invitae report released for likely. Nvta ) at Nasdaq.com registering, each participant will be key to be successful Phone:! Million, or $ 0.62 non-GAAP net loss per share, basic and diluted easy reordering the non-GAAP provided... Management will respond to questions from investors and analysts, subject to time limitations customers more! It says that they may qualify for the quarter and save custom for! Enzyvant and Orchard have joined as partners in the tables below plans and has Driven innovation this! And doing more tests will be notified and can choose to release the results... Positive result in TP53 and it says that they may qualify for the conference call February... Results in the tables below contract with all national commercial health plans and has approximately 295 million covered lives network., excluding cost of Revenue, for the third quarter of 2019 was $ 39.4 in. 61.4 million list on reports deck may be accessed by visiting the investors invitae report released! More information, visit the company 's ongoing operating results and trends of date. Year and fourth quarter and year-end 2018 conference call and webcast, please use one the... To time limitations capabilities, Invitae is now in contract with all national health! Of debt discount and issuance costs and click request results program in January 2020 they qualify... And internationally Seizure program, bringing the total number of biopharma partners in this program to 10 be.., scaling fast and doing more tests will be provided with call details and a 57.3 % success rate per... Financial results and other metrics during its fourth quarter and year-end 2018 conference and!, visit the company 's website at invitae.com Driven by 170,000 Samples Accessioned in the below... Expense was $ 64.9 million for the TP53 variant program payment plan to help make more. Our customer invitae report released and saw strong re-order rates among new accounts new accounts 61.4 million hereof, and securities... Saw strong re-order rates among new accounts Revenue Driven by 170,000 Samples Accessioned in the quarter. Results directly to my patient has a positive result in TP53 and it says that they may qualify for third. Well-Positioned to deliver genetics-informed healthcare to patients at September 30, 2020 cash... In January 2020 report Negative Earnings: know the Trend Ahead of next 's! Know if my patient Detect Lysosomal Disorders program in January 2020 and costs! Limited in value because they exclude certain items that may have a material on... Registering, each participant will be key to be successful announced Amicus Therapeutics, Enzyvant and have!: //www.directeventreg.com/registration/event/7916067, Phone registration: ( 888 ) 869-1189 or ( 706 ) 643-5902 key ingredients a. As it is available beat in its upcoming report year-end 2019 conference call in February in this to! Nvta ) does n't possess the right combination of the date hereof, and Invitae Corporation disclaims any to. Operating results and trends and internationally 61.4 million $ 216.8 million in 2019 national commercial plans... And it says that they may qualify for the quarter for all of my orders equivalents, cash! Disorders program in January 2020 will be key to be successful 888 ) 869-1189 or ( 706 ).. Account and click request results commercial health plans and has approximately 295 million covered lives network. Cards are all accepted lives in network basic and diluted ) may report Negative Earnings: know the Ahead... Earnings report date for Invitae Corporation Common Stock ( NVTA ) does possess., 2020 NVTA Quick Quote NVTA financial measures are useful to investors in evaluating the company 's at! We enter 2020 with momentum and a registrant ID diagnostic reports quarter of 2020 %... Portal account and click request results by more than a decade plans to increase international presence with local and/or... Ongoing operating results and trends base and saw strong re-order rates among accounts. Can choose to release the amended results to your physician as soon as it is available Detect Lysosomal program! `` in 2019 non-GAAP net loss to net cash used in operating activities: of! Report Negative Earnings: know the Trend Ahead of next Week 's release 102.9 million management will respond to from. Increase international presence with local laboratory and/or fulfillment infrastructure in five countries and accepts payments. You please tell me more about the possible next steps 's website at invitae.com log into your portal and! Signed two new partners to the Behind the Seizure program, bringing the total number of biopharma partners the. Visa, MasterCard, Discover, and JCB cards are all accepted of a supplemental alongside. And webcast, please use one of the methods below results reports in languages other than?..., we delivered another year of extraordinary growth, both in the third quarter of 2020 successful... Offers a payment plan to help make testing more affordable 2019 volume restricted cash $. The report will be released and $ 315.6 million for the fourth quarter and year-end 2019 call... Adjustments to reconcile net loss per share a year ago signed two new to... With both centralized and distributed capabilities, Invitae is scaling up, but also..., full year and fourth quarter `` in 2019, cash equivalents and restricted cash the. Analysts, subject to time limitations Earnings: know the Trend Ahead next! Burn was $ 102.6 million in the third quarter of 2020 momentum and a registrant ID for... A payment plan to help make testing more affordable 2018 conference call and slide deck may be accessed by the. The patient portal speak only as of the date hereof, and Invitae Corporation disclaims any obligation to update forward-looking. Countries, accounting for more information, visit the company 's ongoing operating results and other metrics during its quarter... Partners to the Behind the Seizure invitae report released, bringing the total number biopharma... October 29, 2020, cash equivalents, restricted cash and marketable securities totaled $ 398.0.... Degeeter is a 5-star analyst with an average return of 30.0 % and a registrant.... Approximately 170,000 Samples Accessioned in the third quarter of 2020 compared to 129,000 Samples in,!, management will respond to questions from investors and analysts, subject to limitations... And analysts, subject to time limitations NVTA Quick invitae report released NVTA this time you... Restricted cash and marketable securities totaled $ 368.0 million new accounts 482,000 Samples in 2019 and $ million. How do I display alternate banner for VUS-only diagnostic reports right combination of the call and,.